124 related articles for article (PubMed ID: 34669219)
1. Second dose of COVID-19 vaccination in immediate reactions to the first BNT162b2.
Rosa Duque JS; Leung D; Au EYL; Lau YL
Pediatr Allergy Immunol; 2022 Jan; 33(1):e13683. PubMed ID: 34669219
[No Abstract] [Full Text] [Related]
2. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
3. [Erythema multiforme following COVID-19 vaccination (BNT162b2)].
Wunderlich K; Dirschka T
Hautarzt; 2022 Jan; 73(1):68-70. PubMed ID: 34676438
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
5. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
7. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
[TBL] [Abstract][Full Text] [Related]
8. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
9. BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
Walter EB; Talaat KR; Gurtman A
N Engl J Med; 2022 Feb; 386(6):606. PubMed ID: 35045225
[No Abstract] [Full Text] [Related]
10. Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.
Halder A; Imamura H; Condon S; Boroughs K; Nilsson SC; Anderson T; Caterson ID
Intern Med J; 2022 Jan; 52(1):121-124. PubMed ID: 35060290
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
12. Safety and BNT162b2 mRNA COVID-19 vaccination.
Joob B; Wiwanitkit V
Acta Biomed; 2022 Jan; 92(6):e2021485. PubMed ID: 35075060
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
14. BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Mintzker Y
N Engl J Med; 2022 Feb; 386(6):604-606. PubMed ID: 35045224
[No Abstract] [Full Text] [Related]
15. BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Fang SF; Liu N; Du HW
N Engl J Med; 2022 Feb; 386(6):604. PubMed ID: 35045223
[No Abstract] [Full Text] [Related]
16. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
17. More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Taytard J; Prevost B; Corvol H
N Engl J Med; 2022 Mar; 386(12):1191-1192. PubMed ID: 35235722
[No Abstract] [Full Text] [Related]
18. Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
Novembre E; Tosca M; Caffarelli C; Calvani M; Cardinale F; Castagnoli R; Chiappini E; Cravidi C; Del Giudice MM; Duse M; Licari A; Manti S; Martelli A; Ricci G; Pingitore G; Marseglia GL
Ital J Pediatr; 2022 May; 48(1):76. PubMed ID: 35578294
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies.
Declercq J; Tobback E; Vanhee S; De Ruyck N; Gerlo S; Gevaert P; Vandekerckhove L
Allergy; 2022 Jan; 77(1):304-307. PubMed ID: 34543444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
